The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the ...

China-made PD-1 inhibitors just can’t get a clean pass through the FDA.  | China-made PD-1 inhibitors continue to struggle at ...

Following a reportedly bullish assessment from Medicare, Eisai has projected a significant sales increase for Leqembi. Takeda ...

Following a controversy over Covis’ preterm birth drug Makena in the U.S. last year, the European Medicines Agency (EMA) is ...

Right on the heels of a similar move by Johnson & Johnson, GSK is offloading the rest of its stake in the consumer healthcare ...

Seven months after Amgen’s chief medical officer referred to trial results for the company's investigational lung cancer ...

This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and ...

After Moderna last year suffered a loss in its heated patent fight against Pfizer and BioNTech, the mRNA drugmaker can now ...

The company formerly known as First Wave BioPharma has found itself on dry land with a decidedly non-aquatic new moniker. The ...

The FDA has broadened the use of Bristol Myers Squibb’s CAR-T therapy Breyanzi to another type of blood cancer. | The FDA has ...

AbbVie’s newest psoriasis awareness-raising campaign is taking the skin condition out of the spotlight. | AbbVie’s newest ...

Launched amid NF Awareness Month this May, its new campaign “Coping isn’t Care” is aimed at boosting knowledge of ...